A recent scholarly review, published in The Lancet and spearheaded by researchers from University College London (UCL) and UCL Hospitals (UCLH), has ignited discussion regarding the potential for transmitting detrimental brain proteins through blood transfusions. This comprehensive analysis probes whether current safety protocols are sufficient and if additional preventative measures are warranted while further scientific inquiry unfolds into these intricate risks.
Lancet Review Uncovers Potential Amyloid-Beta Transmission in Blood Transfusions
In a groundbreaking review published in The Lancet on August 21, 2026, Professor John Collinge and his esteemed colleagues from UCL and UCLH shed light on the unsettling prospect of amyloid-beta protein transmission via blood transfusions. This protein is intricately linked to both Alzheimer's disease, a severe form of dementia, and cerebral amyloid angiopathy (CAA), a condition characterized by brain hemorrhages.
The research team meticulously examined existing data, including a significant Scandinavian epidemiological study from 2023. This study revealed a heightened risk of brain bleeds in individuals who received blood from donors later diagnosed with multiple brain hemorrhages, a key indicator of CAA. While these findings do not conclusively establish a causal link, they underscore the urgent need for further investigation into the potential transmission pathways of amyloid-beta and CAA through blood transfusions.
The concern stems from historical medical precedents. Cases of iatrogenic, or medically acquired, CAA have been documented globally, with the first living patients identified by a UCL team. These individuals developed unusually early-onset CAA-induced brain bleeds after receiving cadaveric dura mater transplants in their childhood, three to four decades prior. Similarly, Professor Collinge's team reported in 2024 on five patients with acquired Alzheimer's disease, who developed dementia symptoms prematurely following childhood treatments with cadaveric pituitary-derived human growth hormone (c-hGH). Further confirmation came with a 2026 publication detailing an iatrogenic Alzheimer's case with definitive autopsy confirmation. These instances, though rare and linked to discontinued medical practices (cadaveric dura mater use ceased in the UK in 1992, c-hGH in 1985), highlight the inadvertent transmission of amyloid-beta.
The scientists emphasized that contemporary medical procedures have not been thoroughly evaluated for similar risks, primarily due to the significant challenges in developing effective tests for amyloid-beta infectivity.
Drawing parallels to the UK Infected Blood Inquiry report of 2024, which detailed widespread infections of HIV and hepatitis C from contaminated blood, Professor Collinge advocates for proactive safety measures. The inquiry notably praised the UK's swift and preemptive response to variant Creutzfeldt-Jakob disease (CJD), another prion-related illness, by filtering white blood cells from donated blood. This action was taken based on a theoretical risk, guided by the principle that 'no evidence of harm is not evidence of no harm,' a stark contrast to the delayed responses to HIV and hepatitis C risks. Professor Collinge reiterated the importance of transparency regarding potential amyloid-beta transmission risks, urging immediate action to safeguard patient well-being.
This pioneering research by Professor John Collinge and his team serves as a critical reminder of the complexities inherent in medical advancements and the perpetual need for vigilance. The exploration of potential amyloid-beta transmission through blood transfusions, though currently theoretical, necessitates a robust, proactive approach from the medical community. The historical lessons from past medical inquiries, particularly the Infected Blood Inquiry, underscore the paramount importance of early intervention and transparency over waiting for irrefutable evidence of harm. This perspective is not merely about identifying risks but about fostering an environment where patient safety is prioritized above all else, driving continuous research, and adapting clinical practices to ensure the highest standards of care. The potential implications for global blood banking and transfusion practices are significant, urging a collaborative effort to unravel these complex biological mysteries and implement preemptive strategies that safeguard public health.